BUZZ-Sellas Life Sciences shares surge as cancer vaccine extends patient survival in clinical trials
路透社2026/11/17 13:51November 17 - ** Pharmaceutical company Sellas Life Sciences (SLS.O) shares surged 301% to $29.98 in premarket trading
** SLS said its experimental vaccine galinpepimut-S (GPS) helped prolong survival in certain blood cancer patients during late-stage clinical trials (link)
** The vaccine was tested in patients with acute myeloid leukemia (AML), a rapidly growing cancer of the blood and bone marrow
** Sellas said the median survival for GPS-treated patients was 24 months, compared to 14.7 months for the control group
** In this study involving 126 patients, GPS reduced the risk of death by 41% compared to the current best treatment option
** According to the American Cancer Society, about 22,720 people are expected to be diagnosed with AML in 2026 in the US, with around 11,500 deaths from the disease
** As of the previous trading day close, SLS stock has risen 98% so far this year
(For the convenience of non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may contain errors or may not include the required context, Reuters does not guarantee the accuracy of the automated translation text and provides it solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Liberty Global subsidiary VodafoneZiggo swings to Q3 net profit of €1.1 million
Impact Biomedical Holds Special Shareholder Meeting
Natural gas: US demand drop offers limited relief to Europe - Commerzbank

Chinese Yuan: Further gains likely against US Dollar – UOB